Am­gen show­cas­es its last big round of promis­ing KRAS G12C da­ta for so­tora­sib. Next up: A like­ly mar­ket­ing cam­paign for a break­through ther­a­py

Am­gen is show­ing off the last, break­through round of da­ta it has from the piv­otal study for its KRAS G12C drug so­tora­sib in non-small cell lung can­cer — the da­ta they’ll be go­ing to mar­ket with, if reg­u­la­tors come through with an ac­cel­er­at­ed OK soon, which is wide­ly ex­pect­ed.

The da­ta are ar­riv­ing in ad­vance of the sched­uled re­lease for the World Con­fer­ence on Lung Can­cer, cour­tesy of an em­bar­go break on the PR for the da­ta, which sur­faced ear­ly in Chi­na. But that helps il­lus­trate just how ea­ger­ly await­ed the da­ta are as the FDA re­views the re­sults for a drug that cur­rent­ly has “break­through” sta­tus from late last year, putting the pro­gram on a short­cut to a near-term mar­ket­ing de­ci­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER